糖尿病視網膜病變市場規模、佔有率和成長分析（按類型、治療方法、診斷、給藥途徑、最終用戶、分銷管道和地區分類）－2026-2033年產業預測

預計到 2024 年，糖尿病視網膜病變市場規模將達到 101.6 億美元，到 2025 年將達到 108.6 億美元，到 2033 年將達到 185.2 億美元，在預測期（2026-2033 年）內複合年成長率為 6.9%。

由於糖尿病盛行率不斷上升、人口老化以及糖尿病相關視力障礙發生率不斷增加，糖尿病視網膜病變市場預計將迎來顯著成長。主要市場促進因素包括人們對糖尿病的認知不斷提高，以及旨在早期檢測和管理的創新產品的推出。長期高血糖導致的視網膜毛細血管損傷凸顯了有效監測和生活方式改變以降低風險的緊迫性。儘管採取了預防措施，糖尿病視網膜病變仍可能導致不可逆的視力喪失，因此早期療育至關重要。各公司正在投資人工智慧驅動的篩檢解決方案，例如「Check Eye」專案。此外，不斷上漲的醫療保健成本和日益老齡化的人口進一步推動了市場潛力，凸顯了在管理糖尿病相關併發症持續保持警惕和加強教育的必要性。

糖尿病視網膜病變市場促進因素

全球糖尿病視網膜病變市場的主要促進因素之一是全球糖尿病盛行率的不斷上升。隨著糖尿病發生率的持續成長，包括糖尿病視網膜病變在內的相關併發症的發生率也隨之增加，從而推動了對有效篩檢、診斷工具和治療方法的需求。此外，醫療專業人員和患者對糖尿病視網膜病變的認知不斷提高，也促使人們增加對創新治療方法和技術的投資。隨著醫療系統尋求減輕視力喪失的負擔並改善患者預後，對早期發現和管理的日益重視正在推動市場成長。

限制糖尿病視網膜病變市場的因素

全球糖尿病視網膜病變市場面臨的主要限制因素之一是先進診斷和治療方案的高昂成本。視網膜成像和雷射治療等先進技術通常需要大量投資，這限制了患者和醫療服務提供者的獲取途徑，尤其是在發展中地區。此外，這些創新解決方案的報銷難題進一步加劇了經濟障礙，導致診斷和治療延遲。因此，這種經濟障礙不僅影響患者的治療效果，也限制了市場成長，因為醫療系統難以分配足夠的資源來有效應對日益成長的糖尿病視網膜病變盛行率。

糖尿病視網膜病變市場趨勢

糖尿病視網膜病變市場正呈現出一個顯著的趨勢，即優先考慮早期發現和及時干預策略。這一轉變源於人們對該疾病影響的認知不斷提高，以及透過積極措施預防視力喪失的可能性。診斷影像技術的進步在實現快速準確診斷方面發揮關鍵作用，醫療機構也越來越重視定期篩檢計畫和宣傳活動。這種積極主動的方法不僅改善了患者的預後，還有助於開發標靶治療，使早期發現成為現代糖尿病視網膜病變管理策略的基石，最終有助於提高患者的生活品質。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 專利分析
• 技術分析

全球糖尿病視網膜病變市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 非增殖性糖尿病視網膜病變
• 增殖性糖尿病視網膜病變

全球糖尿病視網膜病變市場規模（依治療方法及複合年成長率分類）（2026-2033 年）

• 藥物治療
• 基於設備的治療
• 外科手術
• 其他

全球糖尿病視網膜病變市場規模（按診斷和複合年成長率分類）（2026-2033 年）

• 螢光造影
• 光同調斷層掃瞄
• 其他

全球糖尿病視網膜病變市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 玻璃體內注射
• 玻璃體內植入
• 眼藥水
• 雷射手術
• 其他

全球糖尿病視網膜病變市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 居家醫療
• 其他

全球糖尿病視網膜病變市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球糖尿病視網膜病變市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Oxurion NV（Belgium）
• Sirnaomics（China）
• Alimera Sciences（USA）
• Ampio Pharmaceuticals Inc.（USA）
• Kowa Company Ltd.（Japan）
• Genentech, Inc.（USA）
• Regeneron Pharmaceuticals Inc.（USA）
• Roche Holding AG（Switzerland）
• Allergan PLC（Ireland）
• Pfizer, Inc.（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Heidelberg Engineering GmbH（Germany）
• Optos PLC（UK）
• Canon Inc.（Japan）
• Nidek Co., Ltd.（Japan）
• Bausch+Lomb Incorporated（Canada）

結論與建議

Diabetic Retinopathy Market size was valued at USD 10.16 Billion in 2024 and is poised to grow from USD 10.86 Billion in 2025 to USD 18.52 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The market for diabetic retinopathy is poised for significant growth due to an increasing prevalence of diabetes, an aging population, and a rise in diabetes-related vision issues. Key drivers include heightened awareness of diabetes and the introduction of innovative products aimed at early detection and management. Damage to retinal capillaries from prolonged high blood sugar levels underscores the urgency for effective monitoring and lifestyle modifications to mitigate risks. Despite proactive measures, diabetic retinopathy can lead to irreversible vision loss, highlighting the importance of early interventions. Companies are investing in AI-driven solutions for screening, as exemplified by initiatives like Check Eye. Additionally, escalating healthcare spending and an expanding elderly demographic further stimulate market potential, emphasizing the necessity for ongoing vigilance and education in managing diabetes-related complications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Retinopathy Market Segments Analysis

Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Retinopathy Market

One of the key market drivers for the global diabetic retinopathy market is the rising prevalence of diabetes worldwide. As the incidence of diabetes continues to increase, the associated complications, including diabetic retinopathy, become more prevalent, thereby driving demand for effective screening, diagnostic tools, and treatment options. Additionally, heightened awareness of diabetic retinopathy among healthcare providers and patients has spurred investments in innovative therapies and technologies. This enhanced focus on early detection and management fosters growth in the market, as healthcare systems seek to reduce the burden of vision loss and improve patient outcomes.

Restraints in the Diabetic Retinopathy Market

One significant market restraint for the global diabetic retinopathy market is the high cost associated with advanced diagnostic and treatment options. Cutting-edge technologies, including retinal imaging and laser therapies, often require substantial investment, which can limit accessibility for patients and healthcare providers, particularly in developing regions. Additionally, reimbursement challenges for these innovative solutions further exacerbate financial barriers, leading to delayed diagnosis and treatment. Consequently, this economic obstacle not only hampers patient outcomes but also restricts market growth as healthcare systems struggle to allocate adequate resources to combat the rising prevalence of diabetic retinopathy effectively.

Market Trends of the Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing a notable trend towards prioritizing early detection and timely intervention strategies. This shift is driven by heightened awareness of the condition's impact and the potential for preventing vision loss through proactive measures. As healthcare providers emphasize regular screening programs and educational campaigns, advancements in imaging technologies play a crucial role in facilitating quick and accurate diagnosis. This proactive approach not only enhances patient outcomes but also supports the development of targeted therapies, making early detection a cornerstone of modern diabetic retinopathy management strategies, ultimately contributing to improved quality of life for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Technology Analysis

Global Diabetic Retinopathy Market Size by Type & CAGR (2026-2033)

• Market Overview
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Through Device
• Surgery
• Others

Global Diabetic Retinopathy Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Global Diabetic Retinopathy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravitreal Injections
• Intravitreal Implants
• Topical Eye Drops
• Laser Surgery
• Others

Global Diabetic Retinopathy Market Size by End-Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Diabetic Retinopathy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Diabetic Retinopathy Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heidelberg Engineering GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optos PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb Incorporated (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations